The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden.

ABSTRACT:

Introduction

We sought to estimate the cost-effective price for lecanemab for treating early Alzheimer's disease in Sweden from the perspective of formal care payers.

Methods

We developed a Markov model with states defined by disease severity and care setting. The model was populated by integrated clinical and economic data from Swedish registers. We included patients with biomarker-confirmed Alzheimer's disease and fitted survival models for transitions between model states. Costs in 2023 Swedish kronor (SEK), life-years (LYs), and quality-adjusted LYs (QALYs) over a 10-year time horizon were estimated for standard of care and for lecanemab in addition to standard of care, assuming a maximum treatment duration of 3 years with lecanemab and no treatment effect after treatmen

SUBMITTER: Xia X 

PROVIDER: S-EPMC12450216 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature